Cryo-Save logo CryoSave


News & Events

September 30, 2016

Esperite (ESP) leads international consortium for clinical translation of extracellular vesicles use in various therapies


Extracellular vesicles (EVs) disruptive technology targets unmet needs in neuroinflammatory diseases at lower costs than allogenic stem cell therapies.

Esperite’s business unit The Cell Factory develops EVs-based therapeutics in treatment of drug-resistant epilepsy in children jointly with Bambino Gesù Children’s Hospital, Mario Negri Institute for Pharmacological Research and the Women’s and Children’s Health Department of the University of Padua.


Zutphen, The Netherlands – 30 September 2016

August 29, 2016

ESPERITE N.V. (ESP) announces additional information on envisaged financing


Esperite N.V. (Euronext: ESP, “Esperite” or “the Group”) announced in its press release of 23 August 2016 that it prepares for a significant external funding before year end to which the main shareholder will contribute along with potential other investors.


Zutphen, The Netherlands – 29 August 2016

August 23, 2016

ESPERITE N.V. (ESP) publishes revenue increase of 6% compared to HY1 2015 and 8% compared to HY2 2015


ESPERITE N.V. (ESP) publishes revenue increase of 6% compared to HY1 2015 and 8% compared to HY2 2015

Significant EBITDA improvement


Zutphen, The Netherlands – 23 August 2016

March 17, 2015

ESPERITE financial results for 2014 published, metamorphosis completed, first positive forecast growth at €36mio Revenues (+30%) for 2015



Zutphen, The Netherlands – 17 March 2015


ESPERITE (“Esperite N.V. (Euronext: ESP, “ESPERITE” or “the Company”) strengthens market position of Genoma with acquisitions of exclusive technologies for fully-certified groundbreaking genetic tests.


Stem cell historical CryoSave’s core business now profitable and improving.


Consolidated operations, headcount rationalization, integrated sales and marketing strategies, laboratories integration and processes automatization completed to yield enhanced performance and results.

  2. 1
  3. 2
  4. 14
  5. 15
  6. 16
  7. 28
  8. 29